ERBB2 and breast carcinoma: Also of direct relevance to our study, [poly (I:C)] has been shown to significantly increase the therapeutic activity of an anti-ErbB2 antibody in a mouse model of breast cancer, an outcome that was interpreted by these workers as being due to an increase in the activity of NK and CD8+ cytotoxic T-cells [20].